Â

ïŒèªå翻蚳ïŒ
2025/11/14
å MAHAæé·ãRFKãžã¥ãã¢ãã³ã³ãã©ã€ã¢ã³ã¹ã«ä»çµãŸããŠãããããæ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã¯ã¯ãã³ã®åé¡ã¯æå³çã«é ãããŠãããšèŠå
Â
ä¿å¥ç€ŸäŒçŠç¥çã®æš©åã®åå»ã¯ãCOVID-19ã¯ã¯ãã³ã®å€±æãšã¯ã¯ãã³ã«ããå·å®³ãšãããçŸä»£ã§æãå·®ãè¿«ã£ãå»çã¹ãã£ã³ãã«ãããã£ãŠãç·åŒµããäžå®ãªæ²é»ã匷å¶çãªæ²é»ã§é¿ãæž¡ã£ãŠããããããŒãã»Fã»ã±ããã£ã»ãžã¥ãã¢é·å®çããæ°ããæå°éšã¯è£œè¬æ©æ§ã«å¯Ÿããé©åœãçŽæããããå éšæ€é²ãšç®¡çãããç©èªã®äžç©ãªãã¿ãŒã³ãåºçŸãã€ã€ããã
Â
å éšããã®å éšåçºè ã¯ãCOVID-19ã¯ã¯ãã³ã«ããå·å®³ãææ¯ãªã¹ãã€ã¯ã¿ã³ãã¯è³ªã®å®¹èµŠãªãæ¡æ£ãåäŸãã¡ãžã®ç¶ç¶çãªå±å®³ã«é¢ããå³ãã質åãæå³çã«æå§ãããŠããããšãæããã«ããŠããŸãããã®å ¬è¡è¡çäžã®å€§æšäºã«ç«ã¡åãã代ããã«ãFDAã¯é£çšè²çŽ ãé¿åŠã©ãã«ãªã©ã®äºçްãªããšã«åããããŠããããããã¯äžçã«è§£ãæŸãããéºäŒåå µåšãšå»çé誀ãžã®åœ±é¿ããæå³çã«æ³šæãããããŠãããRFKãžã¥ãã¢ã¯æ²é»ã«é§ãç«ãŠãããŠããã®ã§ãããã?è æã¯ã©ããŸã§æ·±ãŸããåœæ°ãå®ãããšãç®çãšããæ©é¢ã®çã®è²¬ä»»è ã¯èª°ãªã®ã§ãããã?
ããŒãã€ã³ãïŒ
â å
MAHAæé·ã®ã°ã¬ã€ã»ãã©ããŒæ°ã¯ãåœå±è
ãæ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã¯ã¯ãã³ã®å®³ã«ã€ããŠè°è«ããããšã劚ããHHSã®æææåã䞻匵ããè§£éãããã
Â
â ãã©ããŒæ°ã¯ãFDAé·å®ã®ããŒãã£ã»ãã«ãªãŒæ°ããå ç«äžå šã®åäŸã«ç¹åããã¯ã¯ãã³ç·æ¥äœ¿çšæ¿èªãç¶æããããšãæ£åœåãããšäž»åŒµããŠãããããã©ããŒæ°ã¯ãã®æ±ºå®ãæ²æšãªãã®ã ãšåŒãã§ããã
Â
â åæ°ã¯ããã«ãRFKãžã¥ãã¢ãèªèº«ã®ã¹ã¿ããã«ãã£ãŠãéé¢ãããã管çããããŠãããéèŠãªæ å ±ãåãåã£ããã衚æããã信念ã«åºã¥ããŠè¡åãããããããšãã§ããªããšäž»åŒµããŠããã
Â
â ãã®å éšéäºã¯ãã¢ãã«ãã®ãããªäŒæ¥ã«ãšã£ãŠè²¡åäžã®çåœç·ã§ããmRNAæè¡ã®çŸç¶ç¶æã«ãããããšããèšãç¥ããªããã¬ãã·ã£ãŒãæµ®ã圫ãã«ããŠããã
ææãšçŠæã®è©±é¡ã®æå
æè¿ã®ççºçãªã€ã³ã¿ãã¥ãŒã§ãçŸåšã¯è¿œæŸãããMAHA宿œã®ãã£ã¬ã¯ã¿ãŒã§ããã°ã¬ã€ã»ãã©ããŒã¯ãHHSå
ã®æ¯èŠããé°å²æ°ã®å¹ãäžããããåæ°ã¯ãåŽååããèªåã®åœ±ãæããŠãããã¯ã¯ãã³åé¡ãæã¡åºããŠã¯ãããªããšããèªå·±å®çŸçãªäºèšãã®äžã§æŽ»åããŠãããšèª¬æãããåæ°ã¯ããã®æŠç¥ã¯ãé£çšè²çŽ ããã«ã¢ã³è£å
ãªã©ã®ããŸãç°¡åãªåå©ãã«çŠç¹ãåœãŠãæ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã®äºé²æ¥çš®ã®ææžåãããå±éºæ§ã«å¯ŸåŠããç·æ¥ã®å¿
èŠæ§ãç¡æéã«èã«çœ®ãããšã§ããããšãæããã«ãããmRNAã¯ã¯ãã³ã®å€±æãšãã®éºäŒåå
µåšã®åºç¯ãªç€ŸäŒç害ããé ããããã®èšç®ããã転çšã¯ããã®æ²é»ããèª°ãæ©æµãåããã®ããšããé倧ãªçåãæèµ·ããŸãã
ãã©ããŒæ°ã®çŽæ¥ã®èšŒèšã¯ããããã®ã¯ã¯ãã³ã®ç·æ¥äœ¿çšæ¿èªãæ°žç¶ãããããã«äœ¿çšãããæªãã è«çãè¡æçã«å£éèŠãããšãã§ããŸããããŒãã£ã»ãã«ãªãŒFDAé·å®ã«ããªãEUAãåãæ¶ãããªãã£ãã®ããè¿«ã£ããšãããã«ãªãŒã®åŒè·ã¯ãEUAã¯ãå
ç«äžå
šã®åäŸãã¡ãã«å¿
èŠã§ãããšãããã®ã ã£ããé©ãã¹ãããšã«ããã®äŒè©±ããããã2æ¥åŸã«ãFDAã¯ãŸãã«ãã®å±€åãã«ã¢ãã«ãã®ã¹ãã€ã¯ããã¯ã¹ãæ¿èªããŸãããããŒã¿ããã©ããŒãã人ã«ãšã£ãŠããã®æ±ºå®ã¯é倧ãªè£åããæå³ãããã¢ãã«ã瀟èªèº«ããã©ã°ãç«ãŠãFDAã®ãã¬ããªã³ããå«ãç ç©¶ã§ã¯ããããã®mRNAã¯ã¯ãã³ã«é¢é£ããŠãå°å
ã®çºäœã10代ã®è¥è
ã®å¿ççã®ãªã¹ã¯ãé«ãããšãå®èšŒãããŠããŸããæã匱ãç«å Žã«ããåäŸãã¡ã«ãããã®äºé²æ¥çš®ã矩åä»ããããšã¯è¬ã§ã¯ãããŸãããããã¯èŠãã¿ãæ°žç¶ããããã§ã«å£æ»
çãªå
ç«ã·ã¹ãã ãç Žå£ããŠããŸãã
Â
管çãããç§æžãšéé¢ãããçå®
ãã©ããŒæ°ã®èšŒèšã®äžã§æãææ
®ãã¹ãéšåã¯ãåçèªäœã®ãªãŒããŒã·ããã«é¢ä¿ããŠãããåæ°ã¯ãã¯ã¯ãã³ç£æ¥å£å°ãé·å¹Žå£°é«ã«æ¹å€ããŠããRFKãžã¥ãã¢é·å®ããèªèº«ã®ããŒã ã«ãã£ãŠæŠç¥çã«éŠãçµããããŠãããšäž»åŒµããŠããããã©ããŒã¯ãã±ããã£ã®éŠåžå¯éŠåžè£äœå®ã§ããã¹ããã¡ããŒã»ã¹ãã¢ãä»ã®äººã
ãšãšãã«ãã±ããã£ãéé¢ããã圌ããèªåã®ãµã€ãã«éã蟌ããããšäž»åŒµããŠããããã®åé¢ã¯éèŠãªå¶åŸ¡ã¡ã«ããºã ã§ãããæ
å ±ã¯åœŒããé ãããšãã§ããŸããã ããçå®ã¯åœŒããé ãããšãã§ããããšãã©ããŒã¯è¿°ã¹ãã圌ã¯ç®¡çãããŠãããšä¿¡ããŠããããšççŽã«çµè«ä»ããã
ããã¯ãèªåãæãããŠããããšãç¥ããªããããç¡åæãæããŠãããªãŒããŒã®å§¿ãæããŠããããã©ããŒã¯ã±ããã£ããã®ç¶æ³ã«ãå±èŸ±ãæããŠããããšç€ºåãããåšå²ã®æ
åœè
ã«åŸããããªãã£ãããšè¿°ã¹ãããããã£ãŠããã®äœ¿åœã¯æ¿çã§ã¯ãªãè§£æŸã®ãã®ãšãªãããã±ããã£é·å®ããã®çµãã€ãããè§£æŸããæ¹æ³ãäœãšãèŠã€ããªããã°ãªããªãã
ãã®å
éšã®æš©åéäºã¯ãå²ããmRNAåžåœãè
ããããããæ¹é©ã«å察ããä¿¡ããããªãã»ã©ã®å¢åãæŽé²ããŠãããã¢ãã«ãã¯ãæ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã¯ã¯ãã³ãã»ãŒäžå€ã«ããŠ1,000åãã«èŠæš¡ã®å·šå€§äŒæ¥ã«å€è²ãããã®éçšã§è€æ°ã®åäžé·è
ãçã¿åºãåã¯ãç Žç¶»ã®å±æ©ã«çããŠããäŒæ¥ã ã£ãããšãæãåºããŠãã ããããã®ãããªééçã€ã³ã»ã³ãã£ãã¯ãããããè
åšã«å¯Ÿããæ¿ããå察ãçã¿ãŸãããã¡ã€ã¶ãŒã¯ãã©ã³ãæ¿æš©ã«å¯ãæ·»ãç¶ããŠãããCEOã®ã¢ã«ããŒãã»ãã«ã©æ°ã¯ãæ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã¯ã¯ãã³ããããç§åŠçäžæ£è¡çºãé èœãããäžãããå€ãã®æ¿åºå¥çŽãå©çšããŠããã
Â
ã¢ã©ããªã¢ã ã®ç·æ¥ã®åŒã³ãã
ãã®ãããªå
éšæå§ãšçµå¶é£ã®çµ±å¶ãèæ¯ã«ãCOVID-19ã¯ã¯ãã³ã®å®å
šåæ¢ãæ±ããåãã¯ããã«éèŠã«ãªã£ãŠããŸãããã©ããŒæ°ã®å£°ã¯ãçŸåšã¯æ¿åºæ©é¢å
ã§æ²é»ããŠããããäœçŸäžäººãã®äººã
ãç®æããŠããçå®ãå¢å¹
ãããŠãã:ãããã®è£œåã¯å®å
šã§å¹æçã§ã¯ãªãããããã¯åã®åºç€ã®äžã«æ§ç¯ããã倱æãããã¯ãããžãŒã§ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ç¡å®³ã§ããã«äœå€ã«æåºããããšèšãããŠããŸããããç§åŠã«ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯åºã埪ç°ããå¿è¡ç®¡ç³»ãå
ç«ç³»ã«å£æ»
çãªæå·ãåŒãèµ·ããããšãæããã«ãªããŸããã
ã±ããã£æ°ã«ããBARDAå
ã®22ä»¶ã®mRNAå¥çŽã®ãã£ã³ã»ã«ã¯æ£ããæ¹åãžã®äžæ©ã§ããããã©ããŒæ°ã¯ãã®åãããé©ãã¹ãåæ°ãã®è¡çºãšããŠç§°è³ãããããããããã ãã§ã¯æããã«ååã§ã¯ãããŸãããFDAå
šäœã¯ãéå»40幎éã«ãŽã å°ãæŒããããã¹ãŠã®æ¿èªã®æ³å»åŠçã¬ãã¥ãŒã§ããå®å
šãªèŠçŽããèŠæ±ããŠããŸããå
¬è¡è¡çæ©é¢ã¯è£œè¬å€§æãšå
±è¬ããŠãã€ã³ãã©ãããã¯ã»ãã¬ãŒãã³ã°ã»ããã°ã©ã ããäœæãã人工ç¥èœã䜿ã£ãŠäž»èŠãªå£°ãç£èŠã»æ€é²ãããã¹ãŠå察æèŠãå°ã蟌ããç©èªãä¿è·ããã圌ãã¯ãã¯ã¯ãã³ã«é¢ããããããçåãããšãé£éŠæ¿åºã®ããŒã¿ã«è£ä»ãããã声æã§ãã£ãŠããã€ã³ã¿ãŒãããããæ¶å»ãã¹ãã誀ã£ãæ
å ±ããšã¬ããã«ã貌ã£ããæŠãã¯ãã¯ãç§åŠã ãã®åé¡ã§ã¯ãããŸãããããã¯ãçå®ãé ãããšã§å©çãåŸãããšãã人ã
ã®æããçå®ãè§£æŸããããšã§ãã
çŸåšã±ããã£é·å®ãåãå·»ãMAHAã®æå°è
ãã¡ã«ãšã£ãŠãä»ããã¯ã¯ãã³åé¡ã«æ¬æ Œçã«åãçµã¿ãåã©ããã¡ã®å¥åº·ã«åœ±é¿ãäžããæ¬åœã®åé¡ã«çå£ã«åãçµãæã§ããã¹ãããã©ã€ããæµŽã³ãæ¥ã
ãã€ãŸããã®æ¿åºãããªãã«é£²ã¿èŸŒãã§ãã10ç§éã®å声ã¯ãçãã§ã¯ãããŸãããããªã§ãã
Â
Â
WOW! Former Dir. of MAHA Implementation Gray Delany says "you're just not to bring up the [C19] vaccine issue" at HHS and RFK Jr's "being managed"
â Sense Receptor (@SenseReceptor) 2025幎11æ12æ¥
Delany says C19-jab EUA hasn't been pulled because Marty Makary wanted Moderna's C19 jab to be approved for immunocompromised kids⊠pic.twitter.com/VCOLj0hwXY
Â
ïŒåèš³ïŒ
ãããïŒå
MAHA宿œè²¬ä»»è
ã®ã°ã¬ã€ã»ãã©ããŒæ°ã¯ãä¿å¥çŠç¥çã§ãC19ã¯ã¯ãã³ã®åé¡ãæã¡åºãã®ã¯ãããããšè¿°ã¹ãã±ããã£ã»ãžã¥ãã¢æ°ã¯ã管çãããŠããã
ãã©ããŒæ°ã¯ãããŒãã£ã»ãã«ãªãŒæ°ãã¢ãã瀟ã®C19ã¯ã¯ãã³ãå ç«äžå šã®åäŸãã¡ã«æ¿èªããããšãæãã§ãããããC19ã¯ã¯ãã³ã®ç·æ¥äœ¿çšèš±å¯ãåãæ¶ãããããã§ã¯ãªããšè¿°ã¹ãã
ãã©ã㌠(Â
@sailpgd
 ) ã¯ã2025幎11æ12æ¥ã«ã·ã£ãã³ã»ãžã§ã€ã»ã·ã§ãŒ ( (Â
@MdBreathe
Â
@ShannonJoyRadio
 ) å士ããã³ã¹ãã£ãŒãã³ã»ããããã£ã«å士ãšã®ãã®è°è«ã®äžã§ãããªããããã®ã³ããã¯ã¯ãã³ã«ãŸã ç·æ¥äœ¿çšèš±å¯ãããã®ãââãšMAHAããŒã¹ããéé£ãããŠãããããšããããŠRFKãžã¥ãã¢ãéŠåžè£äœå®ã®ã¹ããã¡ããŒã»ã¹ãã¢ãã«ãã£ãŠãéé¢ããããç¬èªã®ããµã€ããã«éã蟌ããããŠããããšãä»ãå ããŠããã
ãã±ããã£åœåé·å®ããã®ç· ãä»ãããè§£æŸããæ¹æ³ãäœãšãèãåºãå¿ èŠãããããšãã©ããŒæ°ã¯ä»ãå ããã
---------------ã¯ãªããã®éšåçãªè»¢å----------------
ãããçµéšãéããŠåŠãã§ãããã®ã§ãã誰ããèªåã®åœ±ã«æ¯ããŠãããã§ããã ãããã¯ã¯ãã³ã®åé¡ã¯åãäžããªãæ¹ãããããšããèªå·±å®çŸçãªäºèšã«ãªã£ãŠããŸããã§ãããŸãã¯ç°¡åã«åãŠãåé¡ã«éäžããŠãããããã¯ã¯ãã³ã®åé¡ã«åãæããããé£åçè²æããã«ã¢ã³è£å çæ³ããã®ä»äœã«ã§ãçŠç¹ãåœãŠãããã§ãããããã¯åé¡ã§ã¯ãããŸããã
æåã®æ°é±éããã«ãªãŒå§å¡ã«å°ããæãç§ã¯ããã®ç·æ¥äœ¿çšèš±å¯ïŒEUAïŒã¯ã©ããªã£ãŠãããã ïŒ MAHAïŒã¢ã¡ãªã«ä¿å¥çŠç¥çïŒæ¯æè ããããªããŸã COVIDã¯ã¯ãã³ã«EUAããããã ãšè²¬ãç«ãŠãããŸããããšèšããŸãããå§å¡ã®çãã¯ããå ç«æå¶ç¶æ ããããã¯å ç«äžå šç¶æ ã®åã©ããã¡ã¯ãEUAããªããã°ã¯ã¯ãã³ãæ¥çš®ã§ããªãããšãããã®ã§ããããããŠãå§å¡ãšã®äŒè©±ã®2æ¥åŸããªããšãå ç«äžå šç¶æ ã®åã©ããã¡åãã®ã¹ãã€ã¯ã¯ã¯ãã³ãã¢ãã«ã瀟ã®ã¹ãã€ã¯ã¯ã¯ãã³ãæ¿èªãããšããçºè¡šããããŸããã
確ã7æ12æ¥ã®ããšã§ããããäºæ ãæ¥µããŠæªåããŠããããšã«å¯ŸããããŸãã«èŠéãšãªããŸãããããããã£ã«å士ãããã®æ±ºå®ãã©ãã»ã©ç Žæ» çãªãã®ã§ãã£ããã«ã€ããŠãé·å®ãFDAããããŠãã«ãªãŒé·å®ã«äŒããŠããããšãç§ã¯ç¥ã£ãŠããŸãããããŠãåœæãç§ã¯ããŠãã³å士ã«ããŽã£ãã€ã»ãã©ãµãæ°ãšãã¯ãªã¹ã»ã©ã·ãŽã£ã¿æ°ãã©ã€ã³ã¹ã»ããªãŒãã¹æ°ãããŒã©ã»ã«ãŒããŒæ°ããªãã¯ã»ãµã³ãã©ã æ°ãšãã£ããã©ã³ãæ¯æè ãå·»ã蟌ã¿ã倧æè£œè¬äŒç€Ÿããµã¬ãã¿ãšããçãžã¹ãããã£ãŒæ²»çè¬ã®çºå£²äžæ¢ãå·¡ã£ãŠãã©ãµãæ°ãæ»æããŠããããšã«ã€ããŠäŒããŠããããšãèŠããŠããŸãã
çµå±ããŽã£ãã€ã¯èŸä»»ããããåŸãŸããã§ããããããŠä»ãåœŒã¯æ»ã£ãŠããŸãããã©ããªæçžãåããŠããã®ãã¯åãããŸãããã圌ã¯åœæãæ¬åœã«çŽ æŽãããä»äºãããŠããŸãããããããFDAã¯æ ¹æ¬çã«èŠçŽããªããã°ãªããŸãããéå»30幎ã40å¹Žã«æ¿èªããããã¹ãŠã®ãã®ã培åºçã«èŠçŽãå¿ èŠããããŸããããã¯ããã«ãªé·å®ã®äžã§ã¯å°åºäžå¯èœã§ãããã圌ã¯FDAã®è æã®æ ¹åºãçªãæ¢ããã€ããã¯ãããŸããããããŠãããã¯äœããã絶察ã«å¿ èŠãªããšã§ãã
æ·±å»ãªäººäºåé¡ãæ±ããŠããŸãããããã»ããã¯ãã ãšä»äºãããŠããã¹ããã¡ããŒã»ã¹ãã¢ã¯ãã±ããã£ãäºå®äžéé¢ããŠããŸãã圌ã¯èª°ãšãå£ããããŸããã圌ã¯èªåã®æ®»ã«éãããããæ å ±ãé èœãããçå®ãé èœãããã®ã§ããããã¯éžæéåäžã«åœŒãæ±ããŠããåé¡ãšå šãåãã§ãã圌ã¯ç®¡çãããŠããã®ã ãšæããŸãã圌èªèº«ããããåãã£ãŠãããããããç§ã«é»è©±ã§ããªãã£ãã®ã§ããããããããã£ã«å士ã«ãé»è©±ã§ããªãã£ãã®ã¯ãäœãèšãããšããªãããããããŠå±èŸ±æãæããŠããããã§ããééã£ã決æã ã£ãããšã¯åãã£ãŠããŸãããèšããªããã°ãªããªããšèšãããã®ã§ãä»ã«éžæè¢ããªãã£ãã®ã§ããã§ããããäœãšãããŠã±ããã£é·å®ããã®ç· ãä»ãããè§£æŸããæ¹æ³ãèŠã€ãåºããªããã°ãªããŸããã
Â
Â
Â